International Collaboration707 (PD-1/VEGF) demonstrates global BIC potential, with early data suggesting significant opportunities for international collaboration.
Pipeline Expansion3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.
Revenue Growth3SBio delivered a strong performance, with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi, and other products.